| News
Forty51 closes first fund totaling 43 million US dollars
19.07.2022
A new Basel-based venture fund, Forty51 Ventures I, has raised a total of 43 million US dollars following a first fund closing. Forty51 invests in European biotech firms with clear clinical pathways. The first investment took the form of early stage financing for Mosanna Therapeutics from Basel.

Forty51 Ventures has announced the first closing of its Biotech Venture Capital Fund I and its first investment. In a press release, the company provides details in connection with a deal worth 43 million US dollars. The core strategy of the company, which was founded in Basel in April 2022, aims to support the founding of start-ups and early stage investments in the biotechnology sector, primarily in Switzerland, France and Germany.
The fund, which is based in Luxembourg, is being advised by a three-strong founding team who boast an extensive network and decades of experience in the area of drug development, transactions and venture capital. In addition, the team works with prominent figures within the industry and a strategic partner in the USA.
Investment in biotech
In addition to the closing, Forty51 has also announced its first investment. Mosanna Therapeutics, a biotech firm also recently founded in Basel, is the beneficiary of this. Forty51 led this early stage financing round. The consortium of investors also includes the London-based firm Stable Asset Management and the Fischli family. Mosanna is working on a small molecule developed by Sanofi to treat patients with metabolic obstructive sleep apnea.
“Forty51 Ventures brings true company building to Europe’s exciting Biotech scene”, comments Erik Serrano-Berntsen, CEO and founder of Stable Asset Management, in the press release. “I have not come across a truly differentiating investment strategy in biotech coupled with such a highly complementary skillset among the founding partners”, he concludes.
Learn more about Life Sciences in Switzerland
Share this article
Sign up to receive our newsletter in your inbox.
You may also be interested in
VectivBio sold for approximately 1 billion dollars
The takeover of VectivBio is now being finalized: the Boston-based firm Ironwood Pharmaceuticals, which specializes in gastrointestinal medicine, has agreed...
Read MoreUniversity of Basel and RocketVax present new Covid vaccine
Researchers from the University of Basel have developed a new concept for a Covid vaccine in collaboration with the biotech...
Read MoreRami Swiss and Elbit Systems now manufacturing in Jura
The newly established company Rami Swiss has inaugurated a new production facility in Courtételle in the canton of Jura together...
Read MoreBasel to become Europe’s Silicon Valley of biotech
Silicon Valley is synonymous with technology and innovation, and home to dozens of Fortune 1000 companies and thousands of startups....
Read MoreRoche and Novartis among global leaders for research spending
In 2022, Roche invested 16 billion euros in research and development overall. This puts the Basel-based life sciences firm in...
Read MoreRoche to found Institute for Human Biology
Roche has announced that it will be establishing the Institute of Human Biology in Basel. Up to 250 employees will...
Read More